Man Group
NVCR icon

Man Group’s NovoCure NVCR Stock Holding History

Man Group’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-15,181
Closed -$271K – 2319
2025
Q1 		$271K Buy
+15,181
New +$345K ﹤0.01% 1963
2024
Q3 		– Sell
-300,171
Closed -$5.14M – 2129
2024
Q2 		$5.14M Sell
300,171
-243,653
-45% -$4.29M 0.01% 998
2024
Q1 		$8.5M Buy
543,824
+386,436
+246% +$5.68M 0.02% 771
2023
Q4 		$2.35M Buy
+157,388
New +$2.11M 0.01% 1228
2023
Q3 		– Sell
-99,857
Closed -$2.88M – 1126
2023
Q2 		$4.14M Buy
+99,857
New +$6.2M 0.01% 957
2023
Q1 		– Hold
0
– – – 883
2022
Q4 		– Sell
-2,990
Closed -$227K – 2141
2022
Q3 		$227K Buy
+2,990
New +$233K ﹤0.01% 1740
2022
Q2 		– Sell
-35,722
Closed -$2.96M – 2304
2022
Q1 		$2.96M Sell
35,722
-49,448
-58% -$3.64M 0.01% 1093
2021
Q4 		$6.39M Sell
85,170
-2,916
-3% -$293K 0.02% 783
2021
Q3 		$10.2M Buy
88,086
+45,727
+108% +$6.91M 0.04% 565
2021
Q2 		$9.4M Buy
42,359
+1,077
+3% +$210K 0.03% 603
2021
Q1 		$5.46M Buy
41,282
+4,275
+12% +$676K 0.02% 643
2020
Q4 		$6.4M Sell
37,007
-32,282
-47% -$4.42M 0.03% 659
2020
Q3 		$7.71M Buy
69,289
+10,415
+18% +$833K 0.03% 597
2020
Q2 		$3.49M Buy
58,874
+33,437
+131% +$2.2M 0.02% 833
2020
Q1 		$1.71M Sell
25,437
-10,949
-30% -$865K 0.01% 943
2019
Q4 		$3.07M Buy
36,386
+26,086
+253% +$2.11M 0.01% 1177
2019
Q3 		$770K Sell
10,300
-34,226
-77% -$2.74M ﹤0.01% 1496
2019
Q2 		$2.82M Buy
44,526
+36,533
+457% +$1.85M 0.01% 1192
2019
Q1 		$385K Sell
7,993
-5,991
-43% -$288K ﹤0.01% 1766
2018
Q4 		$468K Sell
13,984
-156,772
-92% -$5.73M ﹤0.01% 1642
2018
Q3 		$8.95M Buy
170,756
+22,631
+15% +$901K 0.03% 685
2018
Q2 		$4.64M Buy
148,125
+6,208
+4% +$173K 0.02% 989
2018
Q1 		$3.09M Buy
+141,917
New +$3.05M 0.01% 1096

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Man Group's NVCR Position: Q2 2025 in Review

Man Group sold out of NovoCure (NVCR) in Q2 2025, closing a stake of 15,181 shares — an estimated $271K sold.

Man Group first reported a position in NVCR in Q1 2018 and held it in 23 quarters. The position peaked at $10.2M in Q3 2021. 242 funds tracked by Wall St. Rank hold NVCR as of Q2 2025.

  • Man Group reported no remaining NovoCure position as of Q2 2025 after selling out during the quarter.
  • Man Group sold 15,181 NovoCure shares in Q2 2025, an estimated $271K.
  • Man Group first reported a position in NovoCure in Q1 2018 and held it in 23 quarters.
  • Man Group's NovoCure position peaked at $10.2M in Q3 2021.
  • 242 funds tracked by Wall St. Rank held NovoCure as of Q2 2025.

Based on Man Group's 13F filing for Q2 2025, filed 14 Aug 2025.